Press Releases Vaxart, Inc.

Equities

VXRT

US92243A2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.815 ^USD	+0.14%		-5.93%	+42.28%

May. 13	Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13	Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 23	AQ
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results	May. 13	AQ
Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13	May. 07	AQ
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers	Apr. 30	AQ
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3	Mar. 27	AQ
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 20	AQ
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results	Mar. 14	AQ
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14	Mar. 07	AQ
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director	Mar. 06	AQ
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge	Feb. 05	AQ
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate	Jan. 19	AQ
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management	Jan. 16	AQ
Vaxart, Inc. Announces Management Change	Jan. 16	AQ
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	Dec. 21	AQ
Vaxart : Investor Presentation November 2023	Nov. 02	PU
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results	Nov. 02	AQ
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	Nov. 02	AQ
Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2	23-10-26	AQ
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19	23-10-11	AQ
Vaxart : Cantor Healthcare Conference September 2023	23-10-06	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vaxart, Inc.

Equities

VXRT

US92243A2006

Press Releases

Filters